
Introduction: Diabetes mellitus could influence lung function in asthmatic patients, but the data remain conflicting. A better understanding of this interaction is needed to optimize care. The objective of our work is to evaluate the impact of diabetes on the ventilatory function of asthmatic subjects Patients and method: This is a multicenter cross-sectional study with an etiological focus. The collection of information on asthma patients was done prospectively from 01/04/2020 to 31/12/2023. Spirometry was performed according to ATS/ERS recommendations. Statistical analyses used binary linear and logistic regression models. Results: A population of 221 asthmatic patients was collected with a sex ratio of 0.27. The average age of our population is 48.9 ± 15.3 years. Diabetics account for 18.6% of cases. Several conventional and non-conventional spirometric indices are reduced in diabetic asthmatics. FEV1 less than 80% of the predicted value is observed with a significant negative linear correlation between FEV1 levels and glycemic counts. FVC less than 80% of the predicted value is found in 68.3% of diabetics with a significant negative correlation between glycemic figures and FVC values. Multivariate analysis by binary logistic regression showed that hyperglycemia multiplies the risk of deterioration of FVC by 2.2 times. Other spirometric parameters such as maximum expiratory flow rates (DEM25-75, DEM50, DEM75, DEP), VEM3 and VEM6 are reduced to different proportions. The risk of a reduced FEV1/MEV3 ratio is multiplied by 2.4 in diabetics. Conclusion: This research has led to a better understanding of the relationship between diabetes and ventilatory function parameters in adult asthmatic patients. Our results indicate a significant impairment of ventilatory function in the presence of diabetes, which could justify routine screening of lung function in these patients.
COPD is a major public health issue globally, resulting in significant morbidity, loss of productivity, and increased health expenditure. Air pollution is considered the primary factor leading to the development and progression of COPD. While the role of outdoor air pollution was well outlined, studies have looked at how indoor air quality and indoor air pollution can cause or worsen the disease. Even though we know that outdoor air pollution has contributed to COPD, the question remains: how do outdoor air pollution and an increased outdoor air pollution load impact indoor air quality, and how will that impact COPD development and progression, and can indoor air filters tackle that? This narrative review focuses on air pollution, the air quality index, and the impact of environmental pollution on indoor air quality and COPD. We also describe the role of the HEPA filters in tackling indoor air pollution, their mechanism, and their impact on COPD and control of indoor air pollution.
Rationale: Pulmonary arterial hypertension (PAH) is a progressive vascular remodeling disease with elevated pulmonary vascular resistance that is lethal. While therapeutic progress was recently made with endothelin, nitric oxide, and prostacyclin pathway-based therapy for the treatment of PAH, the disease is currently incurable with a high cost of morbidity and mortality. Sotatercept, a new activin receptor IIA-Fc fusion protein, may prove to be a game-changer as a therapeutic agent for the treatment of PAH by regulating the growth factor signaling aberration of PAH. Methods: It is a narrative review of evidence for the drug Sotatercept for Group 1 PAH from a systematic literature search for clinical trials, mechanism studies, and regulatory data up to 2024. Pivotal clinical trials such as PULSAR, SPECTRA, STELLAR, and ZENITH were evaluated for efficacy, safety, and comparative results. Results: Sotatercept is a TGF-β family member ligand trap that rebalances activin/BMP signaling to target vascular remodeling. Clinically, striking effects were shown with exercise (40.8 m improvement in STELLAR 6MWD), pulmonary hemodynamics (PVR reduction of 146-240 dyn•s•cm⁻⁵ in PULSAR), as well as clinical measures (76% reduction of composite morbidity/mortality through ZENITH). On the background with an acceptable drug safety profile of predominantly hematologic effects, as well as injection site reaction, benefits were achieved. Comparison with analyses implies at least similar, if superior in some dimensions, efficacy of current PAH therapies. Conclusion: Sotatercept is a new therapeutic option for PAH as the first drug to act on the activin/BMP pathway. With its strong effect on several clinically relevant end points, it is a "fourth pillar" of PAH therapy. Clinical trials will determine its place in the algorithm, ascertain other combinations, and potentially identify its utility for other types of pulmonary hypertension.
................................................................................................................................... ii DEDICATION ............................................................................................................................... iii ACKNOWLEDGEMENTS ........................................................................................................... iv LIST OF ACRONYMS AND ABBREVIATIONS .................................................................... xiv CHAPTER ONE: INTRODUCTION ......................................................................................... 1 1.0 INTRODUCTION ................................................................................................................. 1 1.1 BACKGROUND ................................................................................................................... 1 1.2 PROBLEM STATEMENT ................................................................................................... 2 1.3 THE AIM OF THE STUDY ................................................................................................. 3 1.4 RESEARCH OBJECTIVES ................................................................................................. 3 1.5 RESEARCH QUESTIONS ................................................................................................... 3 1.6 SIGNIFICANCE OF THE STUDY ...................................................................................... 3 1.7 DEFINITION OF CONCEPTS ............................................................................................. 4 1.8 STRUCTURE OF THE STUDY .......................................................................................... 4 1.9 CONCLUSION ..................................................................................................................... 4 CHAPTER TWO: LITERATURE REVIEW ............................................................................ 5 2.0 INTRODUCTION ................................................................................................................. 5 2.1 THEORETICAL LITERATURE .......................................................................................... 5 2.1.1 VENTILATOR ASSOCIATED PNEUMONIA ............................................................ 5 2.1.2. HAND WASHING ........................................................................................................ 6 2.1.3 ORAL HYGIENE CARE ............................................................................................... 7 2.1.4 POSITION OF THE PATIENT ..................................................................................... 7 2.1.5 ENDOTRACHEAL SUCTIONING PRACTICES ........................................................ 7
Status Asthmaticus, is a medical emergency, an extreme form of asthma exacerbation characterized by hypoxic and hypercapnic respiratory failure with resistance to standard therapy including inhaled selective beta-adrenergic agonists, low dose systemic steroids and usually responds to high dose systemic steroids with continuous nebulization of bronchodilators. Epinephrine, while not significantly advantageous in cases of mild to moderate asthma compared to standard therapy, can be significantly useful in cases of resistant, life-threatening asthma.